Immutep welcomes constructive feedback from German regulator for phase III lung cancer trial
Immutep (ASX:IMM) has welcomed constructive feedback from German regulatory authority, Paul-Ehrlichlnstitut (PEI)…
Immutep Limited (ASX:IMM)
About Immutep Limited
Key Information
IMM In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 18/04/2024 | Price Sensitive PS CHDR to conduct first-in-human phase 1 trial of IMP761 | 299.16KB | 3.4K |
| 17/04/2024 | Positive Feedback received from Spanish Medicines Agency | 173.58KB | 1.8K |
| 11/04/2024 | Ceasing to be a substantial holder | 671.48KB | 4.2K |
| 08/03/2024 | Ceasing to be a substantial holder | 42.52KB | 1.6K |
| 05/03/2024 | Price Sensitive PS First Clinical Data announced from 90mg Dosing of Efti | 253.51KB | 28K |
| 28/02/2024 | Price Sensitive PS Half Yearly Report and Accounts | 2.01MB | 609 |
| 26/02/2024 | Becoming a substantial holder | 170.17KB | 694 |
| 22/02/2024 | Change in substantial holding | 675.37KB | 6.0K |